BUY Caplin Point Laboratories Limited — Sachin Janardan Sarvade, IDBI Capital Markets and Securities
bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: NA (inferred 1 year)25 Sept 2026via NDTV Profit (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days
Advisor consensus · adjacent horizon·25 Sept · today
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·24 Sept · yesterday
Caplin Point's Unit Gets Colombia's INVIMA GMP Compliance Nod for Oncology Drugs
NewsGoogle News·5 Sept · 3w ago
Caplin Point Subsidiary Gets Colombian GMP Certification
NewsGoogle News·1 Sept · 3w ago
Caplin Point Labs schedules AGM with ₹8 per share dividend payout
NewsGoogle News·16 Sept · 1w ago
Caplin Point Labs schedules AGM with ₹8 per share dividend payout
NewsGoogle News·8 Sept · 2w ago
Caplin Point Laboratories: AGM Details and ₹8 Dividend
NewsGoogle News·3 Sept · 3w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.